Buprenorphine can cause withdrawal, but the answer splits into two very different scenarios. The first, called precipitated withdrawal, happens when buprenorphine is started too soon after using another opioid and rapidly strips that opioid from your brain’s receptors. The second happens the way any opioid-type medication causes withdrawal: your body adapts to it over time, and stopping abruptly leaves you in a deficit. How severe either scenario gets depends heavily on timing, dosing strategy, and the specific opioid involved beforehand.
What Precipitated Withdrawal Actually Is
Buprenorphine is a partial agonist at the mu-opioid receptor, meaning it activates the receptor but only to a fraction of the level that full agonists like heroin, oxycodone, or fentanyl do.1PubMed Central. Insurmountable antagonism of human mu opioid receptors by buprenorphine is due to hemi-equilibrium It also has an unusually strong grip on those receptors. When someone who is physically dependent on a full agonist takes buprenorphine, the drug’s high receptor affinity allows it to shove the full agonist off the receptors and take its place. But because buprenorphine only partially activates the receptor, the net effect is a sudden, dramatic drop in opioid stimulation. The brain reads this as withdrawal hitting all at once.
The symptoms of precipitated withdrawal are the same ones you would see in ordinary opioid withdrawal: aching muscles, nausea, vomiting, diarrhea, abdominal cramps, dilated pupils, runny nose, and yawning. The difference is speed. Ordinary withdrawal creeps in over hours or days as the previous opioid leaves the body. Precipitated withdrawal can hit within one to two hours of the first buprenorphine dose and is often more intense, though it typically subsides over the following six to twenty-four hours.2PubMed Central. Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
Why Timing the First Dose Matters So Much
The standard safeguard against precipitated withdrawal is to wait until you are already in moderate spontaneous withdrawal before taking the first dose of buprenorphine. The logic is straightforward: if enough of the full agonist has already cleared your receptors that you are experiencing withdrawal on your own, buprenorphine has less to displace and the net change in receptor stimulation is smaller. Clinicians use a scoring tool called the Clinical Opiate Withdrawal Scale (COWS) to gauge how far along withdrawal has progressed before giving the first dose.
Guidelines vary somewhat on the threshold. A national evaluation of emergency department buprenorphine protocols found that most required a minimum COWS score of 8 before initiation.3PubMed Central. Emergency department‐initiated buprenorphine protocols: A national evaluation Other guidance recommends waiting for a COWS score above 13, representing moderate withdrawal, along with a sufficient time gap since the last full agonist dose.4PubMed. Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting For short-acting opioids like heroin or oxycodone, this usually means waiting at least twelve to twenty-four hours. For longer-acting opioids like methadone, the recommended wait can stretch to several days.
The Fentanyl Problem
Illicit fentanyl has made precipitated withdrawal harder to avoid. Fentanyl is highly fat-soluble, so with chronic use it accumulates in fat and muscle tissue and releases slowly back into the bloodstream over days. The average terminal clearance of fentanyl in people with opioid use disorder takes about seven days and may be even slower in people with higher body mass.5JAMA Network Open. Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl This creates a maddening situation: someone using fentanyl can be showing clinical signs of withdrawal (and have a COWS score that would normally green-light buprenorphine) while still having enough fentanyl seeping out of body stores to keep their receptors partially occupied. When buprenorphine arrives and displaces that residual fentanyl, precipitated withdrawal results.
Research on hospitalized patients confirmed that higher body mass index and higher urine fentanyl concentration were both associated with precipitated withdrawal, even among patients who met the usual COWS threshold before receiving buprenorphine.5JAMA Network Open. Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl A case report further noted that fentanyl’s slow release from body stores leads to a higher risk of precipitated withdrawal compared to other opioids.6PubMed Central. Case Report: Buprenorphine-precipitated fentanyl withdrawal treated with high-dose buprenorphine The practical takeaway is that the old rules of thumb about waiting times and COWS thresholds, developed largely in the era of heroin and prescription pills, are less reliable when fentanyl is involved.
Microdosing to Sidestep Precipitated Withdrawal
Because the traditional approach of waiting for withdrawal before starting buprenorphine is uncomfortable and riskier with fentanyl, clinicians have increasingly turned to a strategy called microdosing, sometimes referred to as the Bernese method. Instead of giving a standard first dose of buprenorphine after a period of abstinence, the idea is to start with very small doses while the person continues using their full agonist, then gradually increase the buprenorphine and taper the other opioid.
The concept works because tiny amounts of buprenorphine slowly claim receptor space over days without displacing enough of the full agonist at any one moment to trigger a withdrawal crisis. An early case series found that patients tolerated this overlapping induction well and reported only mild withdrawal symptoms.7PubMed Central. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method A later case report described a successful induction using a microdosing schedule with no apparent withdrawal at all, even while the patient was gradually reducing illicit use.8PubMed Central. Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach
Microdosing protocols are still being refined and are not yet universally standardized, but they have become common practice in many addiction treatment settings, especially when fentanyl is involved. Some clinicians also use higher initial doses of buprenorphine in emergency settings, reasoning that a robust dose more quickly saturates the receptors and shortens any discomfort. One study of emergency department patients found that precipitated withdrawal occurred in fewer than one percent of cases when higher-dose induction was used, and the few cases that did occur had no association with the dose itself.9JAMA Network Open. High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
Withdrawal When Stopping Buprenorphine Itself
The other kind of withdrawal buprenorphine causes is the more conventional kind: if you have been taking it regularly for weeks or months, your body adjusts to its presence, and stopping abruptly produces opioid withdrawal symptoms. These are similar in character to withdrawal from other opioids, including muscle aches, insomnia, nausea, and restlessness. The timeline, however, is slower than withdrawal from short-acting opioids because buprenorphine leaves the body gradually. Symptoms tend to appear about forty-eight hours after the last dose, peak around the third day, and last up to ten days.10PubMed Central. Buprenorphine withdrawal syndrome.
The intensity is generally described as moderate compared to withdrawal from full agonist opioids. A clinical trial comparing buprenorphine and methadone detoxification found that buprenorphine was associated with less severe withdrawal symptoms overall, and patients with concurrent benzodiazepine dependence were more likely to complete detoxification when treated with buprenorphine than with methadone.11Journal of Clinical Psychopharmacology. Comparison of Buprenorphine and Methadone in the Treatment of Opiate Withdrawal A Cochrane systematic review reached a similar conclusion: buprenorphine and methadone appear to have comparable capacity to ease withdrawal, with no clinically significant difference in treatment completion rates.12PubMed Central. Buprenorphine for the management of opioid withdrawal
How Taper Length Changes the Experience
If stopping buprenorphine is the goal, the speed of the taper has a large effect on how uncomfortable the process is. A clinical trial comparing one-week, two-week, and four-week buprenorphine tapers found that the four-week group experienced a relatively mild and stable course of withdrawal with few spikes in severity. The one-week and two-week groups, by contrast, had sharp increases in withdrawal intensity during the week after their last dose. The four-week group also reported significantly fewer disruptions to sleep.13PubMed Central. Characterizing opioid withdrawal during double-blind buprenorphine detoxification
In younger patients, extending the taper even further has shown benefits. A randomized trial in adolescents and young adults found that a fifty-six-day taper produced better opioid abstinence and treatment retention than a twenty-eight-day taper.14PubMed Central. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults The general principle is intuitive: the more slowly receptor stimulation decreases, the less the body objects. Adjunctive medications like the alpha-2 agonist lofexidine can also help manage acute withdrawal symptoms during the transition period.15PubMed Central. A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms.
It is worth noting that many addiction specialists recommend indefinite maintenance on buprenorphine rather than tapering off, particularly for people at high risk of relapse. The decision to taper is a medical one that depends on individual circumstances, and the withdrawal associated with stopping is not a reason to avoid starting treatment in the first place.
Long-Acting Injectable Buprenorphine and a Built-In Taper
Long-acting injectable formulations of buprenorphine, which release the drug from a subcutaneous depot over weeks, have an interesting side effect when discontinued: their pharmacokinetics create something like a built-in taper. Because the drug leaves the body so gradually after the last injection, the transition is smoother than stopping daily sublingual doses cold turkey.
An observational study of patients discontinuing a monthly injectable formulation found minimal increases in withdrawal severity over the study period. The average peak COWS score was about 5, which falls in the mild range, and it typically peaked five to eight weeks after the last injection.16PubMed Central. Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series The terminal plasma half-life of the monthly formulation is roughly nineteen to twenty-five days, so plasma concentrations decline slowly enough that the body has time to adjust.16PubMed Central. Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series A separate study examining patient experiences after discontinuing extended-release buprenorphine similarly noted that the slow decline in plasma concentrations may function as a natural taper.17Drug and Alcohol Dependence Reports. Discontinuing extended-release buprenorphine: Participant experiences from a mixed-methods observational study
This does not mean the injectable formulation is a pain-free off-ramp from opioid use disorder treatment. Some individuals still experience withdrawal symptoms, insomnia, or cravings in the weeks after their last injection. But the data so far suggest the process is substantially gentler than abruptly stopping daily sublingual buprenorphine.
Why the Naloxone in Combination Products Usually Does Not Cause Withdrawal
Many people prescribed buprenorphine receive it as a combination product that also contains naloxone, a full opioid antagonist. This understandably raises alarm: naloxone is the drug used to reverse overdoses by kicking opioids off receptors, so why would you combine it with a medication meant to treat opioid dependence?
The answer lies in how the two drugs are absorbed. When the combination tablet or film is taken under the tongue as directed, buprenorphine absorbs well through the oral mucosa, but naloxone is poorly absorbed that way and undergoes extensive first-pass metabolism in the liver. Very little active naloxone reaches the brain. Because buprenorphine also has much higher affinity for the mu-opioid receptor than naloxone, the buprenorphine dominates and the naloxone is essentially inert.18PubMed Central. Reconsidering the Usefulness of Adding Naloxone to Buprenorphine.
If someone dissolves the tablet and injects it, however, naloxone’s bioavailability is much higher through the intravenous route. In that scenario, the naloxone can reach the brain in meaningful quantities and precipitate acute withdrawal. This is the intended deterrent: the naloxone component is there to discourage injection misuse, not to cause problems for people taking the medication as prescribed.18PubMed Central. Reconsidering the Usefulness of Adding Naloxone to Buprenorphine. If you are taking sublingual buprenorphine/naloxone correctly and experiencing withdrawal-like symptoms, the naloxone is almost certainly not the cause. Dose timing, missed doses, or interactions with other substances are more likely culprits.
Buprenorphine in Pregnancy and Neonatal Withdrawal
Pregnant individuals with opioid use disorder are often maintained on either methadone or buprenorphine, and a natural concern is whether the baby will experience withdrawal after delivery. The short answer is yes, neonatal abstinence syndrome (NAS) can occur with either medication. But the evidence consistently shows that buprenorphine-exposed newborns have milder outcomes.
A landmark trial published in the New England Journal of Medicine compared neonates exposed to buprenorphine versus methadone during pregnancy. The buprenorphine group required significantly less morphine to manage withdrawal symptoms, had shorter hospital stays (about ten days versus roughly seventeen and a half), and needed treatment for NAS for a shorter duration (about four days versus nearly ten).19PubMed Central. Neonatal abstinence syndrome after methadone or buprenorphine exposure A later meta-analysis confirmed the pattern across multiple studies, finding a lower risk of needing NAS treatment and shorter hospital stays for buprenorphine-exposed newborns compared to those exposed to methadone.20American Journal of Epidemiology. Prenatal Buprenorphine Versus Methadone Exposure and Neonatal Outcomes: Systematic Review and Meta-Analysis
Neither medication eliminates the possibility of neonatal withdrawal entirely, and NAS severity varies from infant to infant. But the data support buprenorphine as the gentler option for the newborn, and this is one of the reasons many obstetric guidelines now list buprenorphine alongside methadone as a first-line treatment for opioid use disorder in pregnancy. The benefits of keeping the mother in stable treatment far outweigh the manageable risks of NAS.
Why Buprenorphine’s Receptor Grip Explains Both Problems
The same pharmacological property that makes buprenorphine effective for treating opioid use disorder is the property that causes both kinds of withdrawal. Buprenorphine binds to the mu-opioid receptor with exceptional affinity and dissociates from it very slowly. Research into the structural basis for this behavior has pointed to specific molecular interactions, including a weakened salt bridge at one receptor site and a strong interaction through buprenorphine’s cyclopropyl group at another, that together account for its low efficacy and tenacious binding.21PubMed Central. Structural Determinants of Buprenorphine Partial Agonism at the μ‑Opioid Receptor
That tight binding is what gives buprenorphine its therapeutic “ceiling effect,” reducing the risk of respiratory depression at high doses and making it far safer than full agonists. It is also what allows buprenorphine to block the euphoria of other opioids if someone relapses while on maintenance therapy. But the flip side is that the same high affinity means buprenorphine rapidly displaces other opioids during induction, and the same slow dissociation means the body grows accustomed to its steady receptor occupancy over time. Every benefit and every withdrawal risk traces back to the same molecular behavior at the receptor level.